Is Bajaj Healthcare overvalued or undervalued?

As of 30 June 2025, Bajaj Healthcare's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued. Key ratios include a PE ratio of 37.00, an EV to EBITDA of 21.56, and a PEG ratio of 1.21, which suggest that while the company is not the cheapest in its sector, it is positioned reasonably compared to its peers. In comparison to its industry peers, Bajaj Healthcare's PE ratio is slightly higher than Sun Pharma's at 35.22 but significantly lower than Divi's Lab's exorbitant 82.67. Additionally, the EV to EBITDA ratio of Bajaj Healthcare is more favorable than that of Sun Pharma, which stands at 24.89. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -13.4% compared to the Sensex's 7.00%, the long-term outlook remains positive, as evidenced by a 1-year return of 50.23%.